You are here

NBI-827104

Neurocrine, Idorsia part ways 2 years after collab's double phase 2 fails

Fierce Biotech

Tue, 10/29/24 - 11:32 am

clinical trials

calcium channel blockers

Neurocrine's $50M bet on Idorsia drug flames out in second PhII

Endpoints

Wed, 12/7/22 - 09:58 am

clinical trials

epileptic encephalopathy

‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data

Fierce Biotech

Fri, 08/5/22 - 10:44 am

Neurocrine Biosciences

clinical trials

essential tremor